Athersys (ATHX) Stock Price, News & Analysis $0.02 0.00 (0.00%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.02▼$0.0350-Day Range$0.02▼$0.4452-Week Range$0.02▼$1.99Volume256,178 shsAverage Volume1.70 million shsMarket Capitalization$1.49 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media About Athersys Stock (NASDAQ:ATHX)Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Read More ATHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHX Stock News HeadlinesDecember 7, 2023 | americanbankingnews.comAthersys (NASDAQ:ATHX) Now Covered by Analysts at StockNews.comNovember 16, 2023 | finance.yahoo.comAthersys Reports Third Quarter 2023 Financial Results and Business HighlightsDecember 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 23, 2023 | bizjournals.comAthersys shares migrate to Pink marketplace for broker-to-broker tradingOctober 20, 2023 | bizjournals.comAthersys shares delisted by Nasdaq Stock MarketOctober 16, 2023 | finance.yahoo.comAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesOctober 10, 2023 | msn.comAthersys crashes after bankruptcy warningOctober 10, 2023 | finance.yahoo.comAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with HealiosDecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 3, 2023 | businesswire.comAthersys Licenses its Animal Health Assets to Ardent Animal HealthOctober 2, 2023 | finance.yahoo.comAthersys Director Jane Wasman Appointed Board ChairSeptember 26, 2023 | finance.yahoo.comAthersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst BlogSeptember 6, 2023 | finance.yahoo.comGrant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney TransplantationAugust 25, 2023 | finance.yahoo.comIs Athersys Inc (ATHX) Significantly Overvalued?August 18, 2023 | marketwatch.comAthersys Shares Tumble 26% After Pricing Public OfferingAugust 18, 2023 | investorplace.comWhy Is Athersys (ATHX) Stock Down 36% Today?August 18, 2023 | seekingalpha.comAthersys shares slide on pricing $3.5 million stock offeringAugust 18, 2023 | finance.yahoo.comAthersys, Inc. Announces Pricing of $3.5 Million Public OfferingAugust 16, 2023 | finance.yahoo.comAthersys Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 11, 2023 | finance.yahoo.comAthersys Appoints Neema Mayhugh, PhD to its Board of DirectorsAugust 11, 2023 | bizjournals.comAthersys executives foresee catalysts that could ease its financial journeyJuly 31, 2023 | businesswire.comAthersys to Host Business Update Conference Call on August 9thJuly 30, 2023 | fool.comAthersys (NASDAQ: ATHX)June 1, 2023 | tmcnet.comPatient Enrollment Begins in Third and Final CohortJune 1, 2023 | finance.yahoo.comPatient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic TraumaMay 23, 2023 | msn.comAthersys restructures debt with supplier, prioritizing multi-stem for stroke treatmentMay 23, 2023 | finance.yahoo.comAthersys Restructures Debt with SupplierSee More Headlines Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2023Today12/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHX CUSIPN/A CIK1368148 Webwww.athersys.com Phone(216) 431-9900Fax216-361-9495Employees24Year Founded1995Price Target and Rating Average Stock Price Target$5.50 High Stock Price Target$5.50 Low Stock Price Target$5.50 Potential Upside/Downside+22,721.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,530,000.00 Net MarginsN/A Pretax Margin-46,304.93% Return on EquityN/A Return on Assets-223.03% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$5.32 million Price / Sales0.28 Cash FlowN/A Price / Cash FlowN/A Book Value($1.33) per share Price / Book-0.02Miscellaneous Outstanding Shares61,720,000Free Float61,700,000Market Cap$1.49 million OptionableOptionable Beta-0.78 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel A. Camardo M.B.A. (Age 54)CEO, Secretary & Director Comp: $796.81kMs. Z. Kasey Rosado (Age 49)Interim Chief Financial Officer Comp: $1.51MMs. Maia A. Hansen M.B.A. (Age 54)M.S., Chief Operating Officer Comp: $962.57kSenthil Ranganathan Ph.D.Vice President of Technical OperationsMr. David Russ M.B.A.Vice President of Supply Chain, Finance & AdministrationDr. Manal Morsy M.B.A.M.D., PH.D., Executive VP & Head of Global Regulatory AffairsDr. Robert Mays Ph.D.Executive VP, Head of Regenerative Medicine & Neuroscience ProgramsMr. Rakesh Ramachandran MSHead of Information Technology & Communications and VPDr. Sarah Busch Ph.D.VP of Regenerative Medicine & Head of Business DevelopmentMs. Ellen GurleyManager of Corporate Communications and Investor RelationsMore ExecutivesKey CompetitorsAvalo TherapeuticsNASDAQ:AVTXTimber PharmaceuticalsNYSE:TMBRPaxMedicaNASDAQ:PXMDGRI BioNASDAQ:GRIChina SXT PharmaceuticalsNASDAQ:SXTCView All CompetitorsInstitutional OwnershipWalleye Capital LLCSold 5,000 shares on 11/21/2023Ownership: 0.000%Armistice Capital LLCSold 1,560,000 shares on 11/15/2023Ownership: 1.702%Simplex Trading LLCBought 100 shares on 11/1/2023Ownership: 0.000%View All Institutional Transactions ATHX Stock Analysis - Frequently Asked Questions Should I buy or sell Athersys stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHX shares. View ATHX analyst ratings or view top-rated stocks. What is Athersys' stock price target for 2024? 1 brokers have issued 1-year price targets for Athersys' stock. Their ATHX share price targets range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 22,721.6% from the stock's current price. View analysts price targets for ATHX or view top-rated stocks among Wall Street analysts. How have ATHX shares performed in 2023? Athersys' stock was trading at $0.84 at the beginning of the year. Since then, ATHX stock has decreased by 97.1% and is now trading at $0.0241. View the best growth stocks for 2023 here. How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Thursday, November, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter. When did Athersys' stock split? Athersys's stock reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is William (B.J.) Lehmann's approval rating as Athersys' CEO? 1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). Who are Athersys' major shareholders? Athersys' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (1.70%), Walleye Capital LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel A Camardo, Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Laura K Campbell and William Lehmann Jr. View institutional ownership trends. How do I buy shares of Athersys? Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ATHX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.